- Home
- SNGX
SNGX
Soligenix Inc.
as 07-26-2024 4:00pm EST
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 2.1M | IPO Year: | 1987 |
| Target Price: | N/A | AVG Volume (30 days): | 7.9M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.83 - $32.00 | Next Earning Date: | 08-19-2024 |
| Revenue: | $699,210 | Revenue Growth: | -31.32% |
| Revenue Growth (this year): | -13.9% | Revenue Growth (next year): | 27.03% |
Latest Soligenix Inc. News
SNGX Breaking Stock News: Dive into SNGX Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
Zacks Small Cap Research
17 days ago
SNGX: Positive Interim Results for HyBryte™ in Investigator-Initiated Study in CTCL; Raising Valuation to $35…
MT Newswires
17 days ago
Top Premarket Gainers
MT Newswires
17 days ago
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires
17 days ago
Soligenix Shares Rally Following Positive Trial Results in Early-Stage Lymphoma
PR Newswire
18 days ago
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
PR Newswire
a month ago
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
PR Newswire
a month ago
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
Compare SNGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNGX Soligenix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.